A study of Bortezomib added to cancer treatment

What we are studying

This study will examine the use of Bortezomib as a treatment for T- lymphoblastic leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy). The goal is to find out whether Bortezomib plus the standard treatment is more effective at treating these forms of cancer than the standard treatment alone.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 1 - 31

Eligibility Criteria

  • Must have newly diagnosed T-Lymphoblastic Leukemia (T-ALL) or T-Lymphoblastic Lymphoma (T-LLy)
  • Must be enrolled on AALL08B1 or Project:
    • Every Child
  • Must not have received certain drugs in the past (ask your doctor for details)
  • Must not have Downs Syndrome or uncontrolled seizures
  • Other restrictions may apply ( ask your doctor for details)

What is involved

  • Treatment with Bortezomib if you are randomized to the experimental arm

Compensation

None

Contact Information

Study Coordinator
Sharon Castellino
Email
scastell@wakehealth.edu
Phone
336-716-4085
Principal Investigator
Sharon Castellino

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.